Latest filing published 29 Oct 2025 for PMV Pharmaceuticals, Inc., €260k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
David Henry Mack (chief executive) discloses dealings in PMV Pharmaceuticals, Inc. to SEC (Form 4). Over a trading history stretching from 18 November 2020 to 27 October 2025, the count stands at 29 filings.
The open-market record consists of 6 sales worth €1.3M, with no purchase. Besides market trades, the filings include 1 share grant and 16 option exercises. Since January 2025: no purchases and 1 sale on the market.
Most recently, on 29 October 2025, the filings show an option exercise worth €260k in PMV Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations